Introduction to HER2 Positive BC

Introduction
Unmet Clinical Need

Introduction

HER2 Positive Metastatic BC: Introduction

Treatment Options for HER2 Positive Metastatic BC Are Expanding, Yet Not All Patients Receive Multiple Lines of Therapy^1-3

<p>Treatment Options for HER2 Positive Metastatic BC Are Expanding, Yet Not All Patients Receive Multiple Lines of Therapy<span class="tooltip"><span class="tooltip-text"><sup>1-3</sup></span><span class="tooltip-content" style="display: none;"><span>1. Kunte S, Abraham J, Montero AJ, et al. Novel HER2-targeted therapies for HER2-positive metastatic breast cancer. <em>Cancer</em>. 2020;126(19):4278-4288.</span><span>2. Swain SM, Baselga J, Kim S-B, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer<em>. N Engl J Med</em>. 2015;372:724-734.</span><span>3. Collins J, Nordstrom B, Kwong J, et al. A real-world evidence study of treatment patterns among patients with HER2-positive metastatic breast cancer [poster and abstract]. Poster presented at: San Antonio Breast Cancer Symposium (SABCS) Virtual Annual Meeting; December 8-11, 2020. <em>Cancer Res</em>. 2021;81(suppl 4). Poster PS7-82.</span></span></span></p>

^aPercentage calculated from the total number of patients across both the THP and TH treatment arms in the CLEOPATRA study; ^bPercentage was calculated by subtracting the percentage of patients with HER2-positive mBC from the Flatiron Health Data Repository who did not go onto 3L therapy from 100.

Unmet Clinical Need

HER2 Positive Metastatic BC: Unmet Clinical Need

Prior to DESTINY-Breast03, Unmet Need Persisted in HER2 Positive Metastatic BC^2,4-9

<p>Prior to DESTINY-Breast03, Unmet Need Persisted in HER2 Positive Metastatic BC<span class="tooltip"><span class="tooltip-text"><sup>2,4-9</sup></span><span class="tooltip-content" style="display: none;"><span>2. Swain SM, Baselga J, Kim S-B, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer<em>. N Engl J Med</em>. 2015;372:724-734.</span><span>4. Perez J, Garrigós<sup> </sup>L, Gion M, et al. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond<em>. Expert Opin Biol Ther</em>. 2021;21(7):811-824.</span><span>5. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. <em>N Engl J Med</em>. 2012;367:1783-1791.</span><span>6. Daniels B, Kiely BE, Tang M, et al. Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort. <em>Breast</em>. 2021;58:106-112.</span><span>7. <span style="background-color: rgb(252, 252, 252);">Lupichuk S, Cheung WY, Stewart D. Pertuzumab and trastuzumab emtansine for human epidermal growth factor receptor-2-positive metastatic breast cancer: contemporary population-based outcomes. </span><em style="background-color: rgb(252, 252, 252);">Breast Cancer</em><span style="background-color: rgb(252, 252, 252);"> (Auckl). 2019;13:1178223419879429.</span></span><span>8. <span style="background-color: rgb(252, 252, 252);">Vici P, Pizzuti L, Michelotti A, et al. A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. </span><em style="background-color: rgb(252, 252, 252);">Oncotarget</em><span style="background-color: rgb(252, 252, 252);">. 2017;8(34):56921-56931.</span></span><span>9. Modi S, Saura C, Yamashita T, et al. Updated results from DESTINY-Breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2-positive metastatic breast cancer [poster and abstract]. Poster presented at: San Antonio Breast Cancer Symposium; December 8-11, 2020. <em>Cancer Res</em>. 2021;81(suppl 4). Abstract PD3-06.</span></span></span></p>

^aNot intended for cross-trial comparison.

Abbreviations

1L = first-line

;

2L = second-line

;

3L = third-line

;

BC = breast cancer

;

HER2 = human epidermal growth factor receptor 2

;

mBC = metastatic breast cancer

;

mPFS = median progression-free survival

;

T-DXd = trastuzumab deruxtecan

;

T-DM1 = trastuzumab emtansine

;

TH = paclitaxel and trastuzumab

;

THP = docetaxel, trastuzumab, and pertuzumab

References

1. Kunte S, Abraham J, Montero AJ, et al. Novel HER2-targeted therapies for HER2-positive metastatic breast cancer. Cancer. 2020;126(19):4278-4288.

2. Swain SM, Baselga J, Kim S-B, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724-734.

3. Collins J, Nordstrom B, Kwong J, et al. A real-world evidence study of treatment patterns among patients with HER2-positive metastatic breast cancer [poster and abstract]. Poster presented at: San Antonio Breast Cancer Symposium (SABCS) Virtual Annual Meeting; December 8-11, 2020. Cancer Res. 2021;81(suppl 4). Poster PS7-82.

4. Perez J, GarrigósL, Gion M, et al. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond. Expert Opin Biol Ther. 2021;21(7):811-824.

5. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783-1791.

6. Daniels B, Kiely BE, Tang M, et al. Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort. Breast. 2021;58:106-112.

7. Lupichuk S, Cheung WY, Stewart D. Pertuzumab and trastuzumab emtansine for human epidermal growth factor receptor-2-positive metastatic breast cancer: contemporary population-based outcomes. Breast Cancer (Auckl). 2019;13:1178223419879429.

8. Vici P, Pizzuti L, Michelotti A, et al. A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. Oncotarget. 2017;8(34):56921-56931.

9. Modi S, Saura C, Yamashita T, et al. Updated results from DESTINY-Breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2-positive metastatic breast cancer [poster and abstract]. Poster presented at: San Antonio Breast Cancer Symposium; December 8-11, 2020. Cancer Res. 2021;81(suppl 4). Abstract PD3-06.